USD 15.2
(-2.56%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 536.38 Million USD | 36.63% |
2022 | 392.57 Million USD | 17.84% |
2021 | 333.14 Million USD | 62.38% |
2020 | 205.16 Million USD | 34.79% |
2019 | 152.21 Million USD | 26.99% |
2018 | 119.86 Million USD | 6.11% |
2017 | 112.96 Million USD | -18.36% |
2016 | 138.37 Million USD | 8.55% |
2015 | 127.47 Million USD | 28.69% |
2014 | 99.05 Million USD | 22.55% |
2013 | 80.83 Million USD | -35.76% |
2012 | 125.81 Million USD | 7.13% |
2011 | 117.44 Million USD | 28.89% |
2010 | 91.11 Million USD | 73.71% |
2009 | 52.45 Million USD | 56.43% |
2008 | 33.53 Million USD | 11.93% |
2007 | 29.95 Million USD | 29.89% |
2006 | 23.06 Million USD | -74.63% |
2005 | 90.89 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 508.85 Million USD | -5.13% |
2024 Q2 | 508.85 Million USD | 0.0% |
2023 Q3 | 536.38 Million USD | 7.82% |
2023 FY | 536.38 Million USD | 36.63% |
2023 Q1 | 497.48 Million USD | 26.72% |
2023 Q2 | 497.48 Million USD | 0.0% |
2023 Q4 | 536.38 Million USD | 0.0% |
2022 Q3 | 392.57 Million USD | 14.63% |
2022 Q1 | 342.48 Million USD | 2.8% |
2022 Q4 | 392.57 Million USD | 0.0% |
2022 FY | 392.57 Million USD | 17.84% |
2022 Q2 | 342.48 Million USD | 0.0% |
2021 Q2 | 259.19 Million USD | 13.32% |
2021 FY | 333.14 Million USD | 62.38% |
2021 Q1 | 228.72 Million USD | 11.48% |
2021 Q4 | 333.14 Million USD | 0.0% |
2021 Q3 | 333.14 Million USD | 28.53% |
2020 Q4 | 205.16 Million USD | 0.0% |
2020 Q2 | 158.51 Million USD | 0.0% |
2020 Q1 | - USD | -100.0% |
2020 FY | 205.16 Million USD | 34.79% |
2020 Q3 | 205.16 Million USD | 29.43% |
2019 Q2 | 122.17 Million USD | -12.07% |
2019 Q4 | 152.21 Million USD | 30.88% |
2019 FY | 152.21 Million USD | 26.99% |
2019 Q1 | 138.94 Million USD | 15.92% |
2019 Q3 | 116.3 Million USD | -4.81% |
2018 FY | 119.86 Million USD | 6.11% |
2018 Q1 | - USD | -100.0% |
2018 Q4 | 119.86 Million USD | 0.0% |
2018 Q2 | 120.09 Million USD | 0.0% |
2017 Q2 | 133.19 Million USD | 0.0% |
2017 Q3 | 112.96 Million USD | -15.19% |
2017 Q1 | 133.19 Million USD | -3.74% |
2017 FY | 112.96 Million USD | -18.36% |
2017 Q4 | 112.96 Million USD | 0.0% |
2016 Q4 | 138.37 Million USD | 0.0% |
2016 FY | 138.37 Million USD | 8.55% |
2016 Q3 | 138.37 Million USD | 11.89% |
2016 Q2 | 123.67 Million USD | 0.0% |
2016 Q1 | 123.67 Million USD | -2.98% |
2015 Q1 | 106.3 Million USD | 7.32% |
2015 Q3 | 119.18 Million USD | 12.11% |
2015 Q4 | 127.47 Million USD | 6.96% |
2015 FY | 127.47 Million USD | 28.69% |
2015 Q2 | 106.3 Million USD | 0.0% |
2014 Q1 | 98.34 Million USD | 21.67% |
2014 FY | 99.05 Million USD | 22.55% |
2014 Q2 | 98.34 Million USD | 0.0% |
2014 Q4 | 99.05 Million USD | 0.0% |
2013 Q1 | 77.82 Million USD | -38.15% |
2013 FY | 80.83 Million USD | -35.76% |
2013 Q3 | 78.43 Million USD | 0.79% |
2013 Q2 | 77.82 Million USD | 0.0% |
2013 Q4 | 80.83 Million USD | 3.06% |
2012 Q3 | 77.52 Million USD | -35.95% |
2012 Q2 | 121.03 Million USD | 0.0% |
2012 FY | 125.81 Million USD | 7.13% |
2012 Q4 | 125.81 Million USD | 62.29% |
2011 FY | 117.44 Million USD | 28.89% |
2011 Q4 | 117.44 Million USD | 0.0% |
2010 Q2 | 69.81 Million USD | 0.0% |
2010 Q4 | 91.11 Million USD | 0.0% |
2010 FY | 91.11 Million USD | 73.71% |
2009 FY | 52.45 Million USD | 56.43% |
2009 Q4 | 52.45 Million USD | 0.0% |
2008 FY | 33.53 Million USD | 11.93% |
2007 FY | 29.95 Million USD | 29.89% |
2006 FY | 23.06 Million USD | -74.63% |
2005 FY | 90.89 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alpha Teknova, Inc. | 38.55 Million USD | -1291.367% |
Alvotech | 1.88 Billion USD | 71.508% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -227.254% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 43.412% |
Dynavax Technologies Corporation | 375.02 Million USD | -43.027% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -2416.381% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -8636.497% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -8636.497% |
SCYNEXIS, Inc. | 55.45 Million USD | -867.333% |
Silver Spike Investment Corp. | 3 Million USD | -17721.133% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -5732.431% |
Journey Medical Corporation | 56.49 Million USD | -849.373% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | -13.72% |
PainReform Ltd. | 2.69 Million USD | -19832.59% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 18.827% |
Pacira BioSciences, Inc. | 704.25 Million USD | 23.837% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -291.892% |
Bright Green Corporation | 6.43 Million USD | -8231.431% |
Embecta Corp. | 2.03 Billion USD | 73.656% |
Safety Shot Inc | 3.89 Million USD | -13681.602% |
Procaps Group, S.A. | 462.06 Million USD | -16.085% |
Cosmos Health Inc. | 30.25 Million USD | -1673.029% |
Theratechnologies Inc. | 98.63 Million USD | -443.787% |
Harrow Health, Inc. | 241.75 Million USD | -121.874% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -6025.925% |
Biofrontera Inc. | 23.13 Million USD | -2218.104% |
DURECT Corporation | 30.4 Million USD | -1664.079% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -10.037% |
Cronos Group Inc. | 43.73 Million USD | -1126.415% |
OptiNose, Inc. | 194.33 Million USD | -176.011% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 34.376% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1007.206% |
RedHill Biopharma Ltd. | 20.97 Million USD | -2456.883% |
Organogenesis Holdings Inc. | 181.36 Million USD | -195.754% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -14119.696% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -921.372% |
Radius Health, Inc. | 804.29 Million USD | 33.309% |
Universe Pharmaceuticals INC | 13.75 Million USD | -3799.761% |
ProPhase Labs, Inc. | 42.54 Million USD | -1160.779% |
Phibro Animal Health Corporation | 725.54 Million USD | 26.071% |
Procaps Group S.A. | 462.06 Million USD | -16.085% |
TherapeuticsMD, Inc. | 14.02 Million USD | -3725.317% |
Viatris Inc. | 27.21 Billion USD | 98.029% |
Rockwell Medical, Inc. | 30.88 Million USD | -1636.889% |
Aytu BioPharma, Inc. | 90.37 Million USD | -493.485% |
SIGA Technologies, Inc. | 57.97 Million USD | -825.166% |
Tilray Brands, Inc. | 892.11 Million USD | 39.875% |
Lifecore Biomedical, Inc. | 219.8 Million USD | -144.034% |
Shineco, Inc. | 47.6 Million USD | -1026.821% |
PetIQ, Inc. | 645.22 Million USD | 16.869% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -244253.839% |
Incannex Healthcare Limited | 5.83 Million USD | -9100.446% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 47.382% |
Alimera Sciences, Inc. | 107.35 Million USD | -399.642% |
Assertio Holdings, Inc. | 148.41 Million USD | -261.407% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -28190.923% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -7534.301% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -6217.461% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -209.358% |
Hempacco Co., Inc. | 18.82 Million USD | -2749.721% |
Talphera, Inc. | 6.29 Million USD | -8427.599% |
Alvotech | 1.88 Billion USD | 71.508% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -210.768% |
Lantheus Holdings, Inc. | 835.25 Million USD | 35.782% |
Currenc Group, Inc. | 177.67 Million USD | -201.89% |
Kamada Ltd. | 109.96 Million USD | -387.764% |
Indivior PLC | 1.95 Billion USD | 72.511% |
Evoke Pharma, Inc. | 9.64 Million USD | -5459.509% |
Flora Growth Corp. | 17.22 Million USD | -3014.54% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -6217.461% |
Evolus, Inc. | 209.68 Million USD | -155.803% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 38.593% |
Akanda Corp. | 12.66 Million USD | -4133.885% |